Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Walter Reinisch, a leading global scientific expert and clinician in the area of Inflammatory bowel disease, (IBD) has joined the Algernon Medical and Scientific Advisory Board.
Dr. Reinisch, MD, graduated at the Medical University of Vienna (MUV), where he finished his training in Internal Medicine and Gastroenterology. After initial scientific studies in oncology at the MUV and the National Cancer Institute, Frederick, MD, he decided to focus his research interest on inflammatory Bowel disease (IBD). Dr. Reinisch is a founding member of the European Crohn’s & Colitis Organization (ECCO) and was assigned as honorary member after having contributed in various positions. He was active in the Scientific and Public Affairs Committee of the United European Gastroenterology (UEG) and headed the Austrian IBD Study Group. Dr. Reinisch is a member of the International Organization For the Study of Inflammatory Bowel Disease (IOIBD).
Dr. Reinisch is an expert in designing, conducting and interpreting the results of clinical trials in IBD. He envisions a customized management of IBD utilizing the innovations of translational medicine. He advocates the implementation of a "common language of inflammatory bowel disease" to improve the communication with patients and between physicians for better care and more robust research outcomes. Dr. Reinisch has also either written or made contributions to over 250 publications on IBD and remains active in all aspects of IBD research.
“I am very pleased that Dr. Reinisch has accepted our invitation to join the Algernon Advisory Board,” said Christopher J. Moreau, CEO of Algernon pharmaceuticals. “His significant clinical background and deep experience in the design and management of human clinical trials for IBD will be very helpful as we move forward with plans for a phase II IBD trial."
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Released April 4, 2019
